- Obama’s regulatory agenda will cost U.S. economy $143B next year: report
- Patriot Act author on James Clapper: Fire, prosecute him
- Russia P.M. Medvedev: No amnesty for political prisoners
- Michigan GOP Senate hopeful reminds government is the ‘servant’
- Christmas, by Congress: Members mull a 15-cent tax on trees
- U.S. unemployment falls to five-year low of 7 percent; 203K jobs added
- World mourns Nelson Mandela and celebrates his life; burial set for Dec. 15
- Bill O’Reilly reminds: Nelson Mandela ‘was a communist’
- John Boehner says GOP should support gay candidates: ‘I do’
- Grass-Whopper: Pan-fried cricket burgers go over big in New York City
Experts veto Avastin as a breast cancer treatment
GAITHERSBURG (AP) - A panel of cancer experts said Tuesday that the government should remove its endorsement of Roche’s drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients.
A Food and Drug Administration panel of experts voted 12-1 in favor of removing the drug’s approval for use against breast cancer alongside chemotherapy.
The FDA is not required to follow the advice of its panel, though it often does.
The negative vote is the first major setback for a blockbuster cancer drug that has racked up approvals for a half dozen forms of the disease. Avastin is also approved for colon, lung, kidney and brain cancer. The panel’s ruling only pertains to Avastin’s use in breast cancer.
Roche scientists argued Tuesday that patients taking Avastin experience improved quality of life as tumor growth and other symptoms are delayed _ but panelists were not convinced.
“The study shows there’s very little benefit to patients _ with significant toxicity risks and no clear survival benefit,” said Natalie Compagni Portis, the panel’s patient representative.
“Avastin should be an option for patients with this incurable disease,” said Charlotte Arnold, in a statement.
Even if the FDA withdraws the drug’s approval for breast cancer, doctors will still have the option to prescribe the drug “off-label.” However, medical societies and hospitals tend to follow FDA guidance, influencing prescribing patterns for thousands of U.S. physicians.
Avastin was Roche’s top-selling cancer drug last year with sales of $5.9 billion.
The FDA in 2008 approved Avastin for breast cancer patients based on a trial showing it extended the amount of time until the disease worsened by more than five months. The decision was considered controversial by some cancer doctors because the drug had not been shown to extend patients’ lives.
As a condition of approval, Roche was required to conduct follow-up studies to demonstrate the benefits of adding Avastin to conventional chemotherapy.
But two follow-up studies recently submitted by the Swiss drugmaker did not show the same degree of delay in cancer progression as earlier studies. Additionally, patients taking Avastin did not show a significant improvement in lifespan, the gold standard of cancer treatment effectiveness.
Panelists said they worried the drug could do more harm than good because of serious side effects, including high blood pressure, fatigue and abnormal levels of white blood cells.
“I think the burden of proof is that a drug is helpful, not that it doesn’t make patients worse,” said panel chair Dr. Wyndham Wilson of the National Cancer Institute. “We have definitive evidence that Avastin causes harmful side effects and we’ve now seen a number of well-done studies that show no advantage to lifespan.”
- Spike in battlefield deaths linked to restrictive rules of engagement
- Activists urge Obama to go rogue, sidestep Congress
- Bill OReilly reminds: Nelson Mandela was a communist
- PRUDEN: British press horrified as London's new mayor dares to proclaim the truth
- Obama administration issues permits for wind farms to kill more eagles
- U.S. pilot scares off Iranians with 'Top Gun'-worthy stunt: 'You really ought to go home'
- MILLER: Obamacare enrollees include 101 members of the House of Representatives
- 'Hunger Games' delivers Obama's message on income inequality
- Inside China: Nuclear submarines capable of widespread attack on U.S.
- Obama downplays IRS scandal, blames Obamacare rollout on 'outdated' agencies
Independent voices from the The Washington Times Communities
A politically conservative and morally liberal Hebrew alpha male hunts left-wing viper
This column will cover anything that has anything remotely to do with the game of baseball, from the game itself to mid-summer trades to offseason moves.
Entertainment News and Reviews from Washington, D.C. and beyond.
Political satirist and Christian apologist Bob Siegel discusses religion and politics.
White House pets gone wild!